Abstract Book

S698

ESTRO 37

activities, using the validated modified RISRAS scale, complemented the obtained data. Results Phantom studies revealed a clinically insignificant dose- buildup and dose variations of < 0.1%. Mean maximum radiation dermatitis RTOG/EORTC scores were significantly reduced from 1.33 to 0.35 in the Hydrofilm compartments (p= < 0.001). Photospectrometric measurements showed significantly reduced maximum erythema severity in favor of Hydrofilm (p= 0.0005). Moist desquamation was completely prevented by Hydrofilm, whereas 6 patients developed moist desquamation in the control compartments and required topical steroids. Exemplary photographs of two patients are given in Figure 1; Hydrofilm dressings were applied laterally in these patients. A significant reduction in patients’ subjective experience of itching and pain was also observed. Side reactions were minor and resulted from shear effects at the peripheral areas of Hydrofilm dressings.

received surgery, different adjuvant treatment modalities, and could be under hormonal treatment. Patients with a second treatment line were excluded. Patients completed the EORTC questionnaires QLQ-C30 and QLQ-CR23 once during the treatment fo llow-up period. Sociodemographic and clinical data were also recorded Sociodemogrpahic and clinical data, and the QL questionnaires results were summarized using descriptive statistics. To identify factors related with future perspective and with global quality of life, univariate logistic regression analyses were performed with the categorized scores as response variables and sociodemographic, clinical and QL in the questionnaires as explanatory variables. Multivariate logistic regression models were also performed to complement the analyses, including in the model those factors that resulted significant in the univariate, and using backward regression method. Results 243 patients from 259 candidates were evaluated QL mean scores were high in most QL areas. Moderate limitations occurred in global QL, sleep disturbance, future perspective, sexual functioning and enjoyment (affectation > 30). Light affectation (between 20 and 29 points) appeared in emotional functioning, fatigue, pain and systemic therapy side effects. Mean future perspective was 65.2, and mean global QL 70.9. Main factors related to future perspective were emotional functioning (R2 0.52), fatigue (0.30), breast symptoms (0.29), body image (0.27) and social functioning (0.26); and related to global QL fatigue (0.47), pain and physical functioning (0.31), emotional and social functioning(0.27). A model that includes the QL areas of emotional, social functioning and breast symptoms offers an explanation of the future perspective variance (R2 0.56). A model that includes the QL areas of physical and emotional functioning, and fatigue, offers an explanation of the global QL variance (R2 0.50). Conclusion Patients’ QL was generally satisfactory. Limitations appeared more in emotional aspects. QL in premenopausic early stages breast cancer might benefit from a mutlidisciplinary treatment. These results are in line with those found in the literature in pre-menopausal breast cancer patients with a shorter follow-up period and/or patients in a wider age range EP-1266 Results of intraoperative radiotherapy given as a boost after breast conserving-surgery K. Onthong 1 , K. Saksornchai 1 , C. Chakkabat 1 , C. Nantavithya 1 , K. Shotelersuk 1 1 Chulalongkorn University, Department of Radiology, Bangkok, Thailand Purpose or Objective Whole breast irradiation after breast-conserving surgery (BCS) with external beam boost of 10-16 Gy is currently the standard treatment. Intraoperative radiation therapy (IORT) is one of the accelerated partial breast irradiation techniques. This study aimed to evaluate the local recurrence rate, overall survival rate, toxicity and cosmetic outcome of IORT as a boost followed by whole breast irradiation in patients who received breast- conserving surgery. Material and Methods This is a retrospective study. Between Dec 2009 and March 2017, eighty-one patients who underwent breast- conserving surgery with IORT as a boost were enrolled in this study. For IORT , a single dose of 20 Gy was delivered using 30-50 kV photon beam, intraoperatively. All patients received whole breast radiation of 42.5 - 50 Gy over four to five weeks. The primary endpoint was 3-year

Conclusion Prophylactic application of Hydrofilm in adjuvant radiotherapy of breast cancer patients may reduce or even prevent radiation dermatitis. EP-1265 Quality of Life in long term premenopausic early stages breast cancer survivors. QL determinants. J.I. Arraras 1 , A. Manterola 2 , J.J. Illarramendi 3 , G. Asin 2 , E. Salgado 3 , S. De la Cruz 3 , B. Ibañez 4 , R. Vera 3 , M.A. Dominguez 2 1 Complejo Hospitalario de Navarra, Radiotherapeutic Oncology, , Spain 2 Complejo Hospitalario de Navarra, Radiotherapeutic Oncology, Pamplona, Spain 3 Complejo Hospitalario de Navarra, Medical Oncology, Pamplona, Spain 4 Fundación Miguel Servet-NavarraBiomed, Methodology, Pamplona, Spain Purpose or Objective Cancer survivors’ Quality of Life(QL) is a key research and intervention area nowadays. QL is considered especially important in long-term breast cancer survivors who were pre-menopausal at diagnosis:. Few studies have assessed QL in long-term premenopausal breast cancer survivors. Worries about future health are considered one of the main QL dimensions in breast cancer. Few studies have analysed factors related to future perspective and global QL in young early stages breast cancer patients. Material and Methods A consecutive sample of 259 stage I-III breast cancer patients was addressed. Patients were premen opausal at diagnosis and had finished treatment 5 to 20 yearsbefore. They were relapse-free. Patients might have